Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $70.00 price target on Ultragenyx Pharma (NASDAQ: RARE).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
